|
441 |
Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials Enthalten in Acta diabetologica Bd. 54, 27.7.2017, Nr. 10, date:10.2017: 933-941
|
|
|
442 |
Migräneprophylaxe durch CGRP-Signalweg-Blockade in Phase-III-Studie bestätigt Enthalten in Schmerzmedizin Bd. 34, 22.1.2018, Nr. 1, date:2.2018: 12
|
|
|
443 |
Migränetherapie: Placeboeffekt nutzen, Noceboeffekt kennen! Enthalten in Der Neurologe & Psychiater Bd. 18, 3.10.2017, Nr. 9-10, date:10.2017: 18
|
|
|
444 |
Mineralocorticoid Receptor Blockade in End-Stage Renal Disease Enthalten in Current hypertension reports Bd. 19, 27.4.2017, Nr. 5, date:5.2017: 1-11
|
|
|
445 |
Minimal sufficient balance randomization for sequential randomized controlled trial designs: results from the ESCAPE trial Enthalten in Trials Bd. 18, 2.11.2017, Nr. 1, date:12.2017: 1-6
|
|
|
446 |
Mitteilungen des BDE Enthalten in Der Diabetologe Bd. 13, 26.4.2017, Nr. 3, date:5.2017: 222-225
|
|
|
447 |
Mittelfußschmerz bei jedem Spaziergang Enthalten in MMW - Fortschritte der Medizin Bd. 159, 30.10.2017, Nr. 3, date:11.2017: 20
|
|
|
448 |
MM aktuell Enthalten in Manuelle Medizin Bd. 50, 2.9.2012, Nr. 4, date:8.2012: 353-355
|
|
|
449 |
Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland Enthalten in Advances in therapy Bd. 34, 3.10.2017, Nr. 10, date:10.2017: 2316-2332
|
|
|
450 |
Modeling Omitted and Not-Reached Items in IRT Models Enthalten in Psychometrika Bd. 82, 15.11.2016, Nr. 3, date:9.2017: 795-819
|
|